

In the Claims:

1. (currently amended) ~~Film-shaped~~ A film-shaped, mucoadhesive administration form containing a cannabis extract or a cannabis oil.
2. (currently amended) ~~Administration~~ The administration form according to claim 1, ~~characterized in that it has~~ wherein said administration form comprises a polymer matrix ~~which serves as~~ , said polymer matrix being an active substance reservoir and ~~[[has]]~~ having mucoadhesive properties.
3. (currently amended) ~~Administration~~ The administration form according to claim 2, ~~characterized in that the~~ wherein said polymer matrix contains at least one polymer being or more polymers which are water-soluble and/or swellable in an aqueous media, said polymers ~~preferably being~~ selected from the group ~~comprising~~ consisting of starch and starch derivatives, dextran, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or propyl cellulose, polyacrylic acid, polyacrylates, polyvinyl pyrrolidones, polyethylene oxide polymers, polyacrylamides, polyethylene glycol, gelatine, collagen, alginates, pectins, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar-agar, agarose, carrageenan[[,]] and natural gums, and wherein said administration form comprises said [[the]] polymer at a portion of preferably being 5 to 95%-wt, especially preferably 15 to 75%-wt.
4. (currently amended) ~~Administration~~ The administration form according to ~~any one of the preceding claims, characterized in that it~~ claim 1, wherein said administration form contains the cannabis extract or the cannabis oil in an amount of 0.5 to 50%-wt; ~~preferably in an amount of 1 to 30%-wt.~~
5. (currently amended) ~~Administration~~ The administration form according to ~~any one of the preceding claims, characterized in that it~~ claim 1, wherein said administration form further contains at least one substance or more substances selected from the group consisting of ~~[[the]]~~ flavourings, odorous substances and aromatics, ~~especially from the group comprising~~ menthol, eucalyptol, limonene, phenyl ethanol, camphene, pinene, ~~seasoning aromatics such as~~ n-butyl phthalide or cineol, ~~as well as~~ eucalyptus oil and thyme oil, methyl salicylate, turpentine oil, camomile oil, ethyl vanillin, 6-methyl coumarin, citronellol, and acetic acid n-butyl ester.
6. (currently amended) ~~Administration~~ The administration form according to ~~any one of the preceding claims, characterized in that~~ claim 1, wherein the layer thickness

thereof is 0.01 to 2 mm, preferably 0.05 to 0.5 mm.

7. (currently amended) ~~Administration~~ The administration form according to ~~any one of the preceding claims, characterized in that it~~ claim 1, wherein said administration form further contains at least one or more inactive ingredient ingredients selected from the group consisting of [[the]] fillers, colourants, emulsifiers, plasticizers, sweeteners, preservatives, pH regulators, permeation-enhancing substances, and antioxidants.

8. (currently amended) ~~Administration~~ The administration form according to ~~any one of the preceding claims, characterized in that it~~ claim 1, wherein said administration form has a multilayer structure[[,]] with at least one layer having an active agent content.

9. (original) Use of a cannabis extract or of a cannabis oil for the production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of: conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

10. (currently amended) Use of a cannaboid active agent, ~~preferably from the~~ selected from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromen, for the production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of:

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and

opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

11. (currently amended) [[Use]] The use according to claim 9 or 10, characterized in that, wherein the administration form is an administration form according to ~~any one of claims 2 to 8~~ claim 2.

12. (currently amended) [[Use]] The use according to ~~any one of claims 9 to 11, characterized in that~~ claim 9, wherein the treatment is effected by application of the administration form to the oral mucosa, ~~especially sublingually or buccally~~.

13. (currently amended) Use of an administration form according to ~~any one of claims 1 to 8~~ claim 1 for therapeutic treatment, ~~especially for the treatment of:~~

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

14. (currently amended) Use of a film-shaped, mucoadhesive administration form containing a cannaboid active agent, ~~preferably~~ selected from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromen, for therapeutic treatment, ~~especially for the treatment of:~~

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

15. (currently amended) ~~[[Use]]~~ The use according to claim 14, ~~characterized in that wherein~~ the administration form is an administration form according to ~~any one of claims 2 to 8~~ claim 2.

16. (currently amended) ~~[[Use]]~~ The use according to ~~any one of claims 13 to 15,~~ ~~characterized in that~~ claim 13, wherein the application is carried out on the oral mucosa, ~~especially sublingually or buccally~~.

17. (new) The administration form according to claim 3, wherein said administration form comprises said polymer at a portion of 15 to 75%-wt.

18. (new) The administration form according to claim 4, wherein said administration form contains the cannabis extract or the cannabis oil in an amount of 1 to 30%-wt.

19. (new) The administration form according to claim 5, wherein said flavourings, odorous substances and aromatics are selected from the group consisting of menthol, eucalyptol, limonene, phenyl ethanol, camphene, pinene, seasoning aromatics eucalyptus oil, thyme oil, methyl salicylate, turpentine oil, camomile oil, ethyl vanillin, 6-methyl coumarin, citronellol, and acetic acid n-butyl ester.

20. (new) The administration form according to claim 19, wherein said seasoning aromatics are selected from the group consisting of n-butyl phthalide and cineol.

21. (new) The administration form according to claim 6, wherein the layer thickness is 0.05 to 0.5 mm.

22. (new) The use according claim 12, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application or buccal application.

23. (new) The use according to claim 10, wherein the administration form is an administration form according to claim 2.

24. (new) The use according to claim 10, wherein the treatment is effected by application of the administration form to the oral mucosa.

25. (new) The use according claim 24, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application or buccal application.

26. (new) The use according claim 16, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application or buccal application.

27. (new) The use according to claim 14, wherein the application is carried out on the oral mucosa.

28. (new) The use according claim 27, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application or buccal application.